Haematologica (Jun 2013)
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
- Sara Bringhen,
- Maria Victoria Mateos,
- Sonja Zweegman,
- Alessandra Larocca,
- Antonietta Pia Falcone,
- Albert Oriol,
- Davide Rossi,
- Maide Cavalli,
- Pierre Wijermans,
- Roberto Ria,
- Massimo Offidani,
- Juan Jose Lahuerta,
- Anna Marina Liberati,
- Roberto Mina,
- Vincenzo Callea,
- Martijn Schaafsma,
- Chiara Cerrato,
- Roberto Marasca,
- Luca Franceschini,
- Andrea Evangelista,
- Ana-Isabel Teruel,
- Bronno van der Holt,
- Vittorio Montefusco,
- Giovannino Ciccone,
- Mario Boccadoro,
- Jesus San Miguel,
- Pieter Sonneveld,
- Antonio Palumbo
Affiliations
- Sara Bringhen
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
- Maria Victoria Mateos
- Servicio de Hematología, Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Spain
- Sonja Zweegman
- Department of Hematology VU University Medical Center, Amsterdam, The Netherlands
- Alessandra Larocca
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
- Antonietta Pia Falcone
- IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Unità di Ematologia, San Giovanni Rotondo, Italy
- Albert Oriol
- Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
- Davide Rossi
- Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
- Maide Cavalli
- Divisione di Ematologia, Ospedale Ferrarotto, Università di Catania, Catania, Italy
- Pierre Wijermans
- Department of Hematology, Haga Hospital, The Hague, The Netherlands
- Roberto Ria
- University of Bari “Aldo Moro” Medical School Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, Policlinico, Bari, Italy
- Massimo Offidani
- Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy
- Juan Jose Lahuerta
- Hospital 12 de Octubre, Madrid, Spain
- Anna Marina Liberati
- Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Perugia, Perugia, Italy
- Roberto Mina
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
- Vincenzo Callea
- U.O. Ematologia, Azienda Ospedaliera “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy
- Martijn Schaafsma
- Medical Spectrum Twente, Enschede, The Netherlands
- Chiara Cerrato
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
- Roberto Marasca
- Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
- Luca Franceschini
- Hematology, Tor Vergata University Hospital, Roma, Italy
- Andrea Evangelista
- Unità di Epidemiologia dei Tumori, A.O.U. San Giovannni Battista e CPO, Piemonte, Torino, Italy
- Ana-Isabel Teruel
- Hospital Clinico de Valencia, Valencia, Spain
- Bronno van der Holt
- HOVON Data Center, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
- Vittorio Montefusco
- Ematologia, Fondazione IRCCS Istituto Tumori, Milano, Italy
- Giovannino Ciccone
- Unità di Epidemiologia dei Tumori, A.O.U. San Giovannni Battista e CPO, Piemonte, Torino, Italy
- Mario Boccadoro
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
- Jesus San Miguel
- Servicio de Hematología, Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Spain
- Pieter Sonneveld
- HOVON Data Center, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
- Antonio Palumbo
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy
- DOI
- https://doi.org/10.3324/haematol.2012.075051
- Journal volume & issue
-
Vol. 98,
no. 6
Abstract
Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these patients, treatment-related side effects are frequent and full drug doses difficult to tolerate. We retrospectively analyzed data from 1435 elderly patients enrolled in 4 European phase III trials including thalidomide and/or bortezomib. After a median follow up of 33 months (95%CI: 10–56 months), 513 of 1435 patients (36%) died; median overall survival was 50 months (95%CI: 46–60 months). The risk of death was increased in patients aged 75 years or over (HR 1.44, 95%CI: 1.20–1.72; P
